Bone Metastases Articles

LDH a Predictor for OS in mCRPC Following Radium-223
Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.
Radium-223 Plus Anti-VEGF Therapy Reduces Bone Turnover in Advanced RCC
Patients with advanced renal cell carcinoma with bone metastases had reductions in bone-turnover markers when treated with radium-223 dichloride and a VEGF inhibitor, although the incidence of symptomatic skeletal events remained high.
Less Frequent Zoledronic Acid Not Linked to Increased Skeletal Events for Patients With Bone Metastases
Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, those who used zoledronic acid every 12 weeks, compared with the standard dosing interval of every 4 weeks, did not experience an increased risk of skeletal-related events over 2 years.
RANKL Targeting Aims Beyond Bone Health
Inhibiting RANK signaling has proved a useful strategy in preventing the debilitating skeletal-related events that are associated with bone metastases in many patients with cancer.  
A follow-up analysis of the benefits of adding denosumab to aromatase inhibitor therapy has found that the agent not only helps to prevent fractures, it reduces the risk of recurrence and death in postmenopausal women with HR-positive breast cancer.
Fluoride PET/CT Scan Could Guide Treatment Selection in Bone Metastatic CRPC
Bone marrow failure may occur following treatment with radium-223 in a portion of patients with metastatic castration-resistant prostate cancer who have high skeletal tumor burden.
Bayer Restores Access to Radium-223 for Prostate Cancer
Access to radium-223 dichloride has been restored following a temporary suspension in production by its manufacturer Bayer HealthCare Pharmaceuticals to adjust its manufacturing process to meet certain quality standards that the company has in place.
Radium-223 Production Halted Due to Manufacturing Glitch
Production of the prostate cancer drug radium-223 has been temporarily suspended by its maker, Bayer HealthCare Pharmaceuticals, due to a manufacturing problem.
MRI-Guided Ultrasound Relieves Pain of Bone Metastases
An MRI-guided focused ultrasound approach using heat to alleviate the pain commonly associated with bone metastases has proven to be safe and effective in a multi-center phase III clinical trial, yielding a 64% response rate.
The dosing frequency of zoledronic acid can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.
Publication Bottom Border
Border Publication